Status:
COMPLETED
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
Lead Sponsor:
Bayer
Conditions:
Neovascular Age-related Macular Degeneration
Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which data already collected from people with the eye disorders below are studied. In observational studies, only observations are made without participants receiving...
Eligibility Criteria
Inclusion
- All patients with the diagnosis of nAMD or RVO (Branch or Central) who are patients of Dr. Tom Sheidow listed in the EyeDoc EHR with available patient records from Jan 1, 2009 to May 31, 2023.
Exclusion
- Not applicable.
Key Trial Info
Start Date :
November 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 29 2024
Estimated Enrollment :
1350 Patients enrolled
Trial Details
Trial ID
NCT06495203
Start Date
November 2 2023
End Date
February 29 2024
Last Update
July 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer
Mississauga, Canada